title: Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections.
abstract: A total of 200 samples of Candida spp. that are responsible for fingernail infections were isolated in Belo Horizonte, MG, Brazil from April 2004 to May 2005. The samples were identified by routine microbiological techniques and had the following distribution: Candida parapsilosis (40.5%), C. albicans (31.5%), C. tropicalis (26%), and C. guilliermondii (2%). We performed in vitro susceptibility tests with ciclopiroxolamine, terbinafine, ketoconazole, itraconazole, and fluconazole using the CLSI (Clinical and Laboratory Standards Institute) and EUCAST (European Committee on Antibiotic Susceptibility Testing) methodologies. The percentages of agreement between the two methodologies varied from 48 to 100% (the percentage increased to more than 60% for the majority of the samples). Percentages of agreement between the methodologies lower than 60% were seen with ketoconazole (57%) and itraconazole (48%) for samples of C. albicans and with fluconazole (54%) for samples of C. tropicalis. In general, we observed higher agreement between the values of the MICs obtained with both methodologies for ciclopiroxolamine and terbinafine for all tested species. With azoles, lower percentages of agreement between the methodologies were observed for samples C. albicans and C. tropicalis.
authors.affiliation: Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, PO Box 486, 31270-901 Belo Horizonte, MG, Brazil.
authors.forename: Valda Teixeira
authors.initials: VT
authors.lastname: Figueiredo
authors.forename: Daniel
authors.initials: D
authors.lastname: de Assis Santos
authors.forename: Maria Aparecida
authors.initials: MA
authors.lastname: Resende
authors.forename: Júnia Soares
authors.initials: JS
authors.lastname: Hamdan
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology*; D001938:Brazil; D002175:Candida / Q000187:drug effects* / Q000254:growth & development; D002177:Candidiasis / Q000382:microbiology*; D000077768:Ciclopirox; D015725:Fluconazole / Q000494:pharmacology; D006229:Hand Dermatoses / Q000382:microbiology; D006801:Humans; D017964:Itraconazole / Q000494:pharmacology; D007654:Ketoconazole / Q000494:pharmacology; D008825:Miconazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009281:Naphthalenes / Q000494:pharmacology; D014009:Onychomycosis / Q000382:microbiology*; D011728:Pyridones / Q000494:pharmacology; D000077291:Terbinafine
chemical_list: D000935:Antifungal Agents; D009281:Naphthalenes; D011728:Pyridones; D000077768:Ciclopirox; D017964:Itraconazole; D008825:Miconazole; D015725:Fluconazole; D000077291:Terbinafine; D007654:Ketoconazole